NY Times
NOVEMBER 27, 2020
Court filings reveal consultants’ talk of a records purge during the opioid crisis, and shed new light on sales advice given to the billionaire Sackler family and their drug company, Purdue Pharma.
pharmaphorum
NOVEMBER 2, 2020
The UK drugs regulator has awarded a £1.5 million tender to a software company for an artificial intelligence tool that will be used to process “the expected high volume of COVID-19 vaccine adverse drug reactions (ADRs).”. The tender awarded to Maidenhead, Berkshire-based GenPact UK aims to “ensure that no details from the ADRs…are missed” as the UK prepares to start rolling out COVID-19 vaccines – assuming their safety and efficacy is supported in late-stage trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
NOVEMBER 10, 2020
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find a solution that fits. If your colleagues would like to…. The post Thinking of signing your company up for DrugPatentWatch? appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 16, 2020
It is hoped that the move will help to tackle the persistent symptoms – such as fatigue and brain fog – suffered by people who have developed the condition
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
NOVEMBER 12, 2020
A leader from the AI technology firm discusses how life-sciences pros are harnessing AI to help continue their work in the face of the pandemic.
Eye on FDA
NOVEMBER 17, 2020
Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. Last week Pfizer and BioNTech announced findings from the first interim analysis of the Phase III studies of their candidate vaccine for COVID-19 demonstrating high efficacy levels followed this week by a similar announcement by Moderna.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 27, 2020
A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.
Drug Patent Watch
NOVEMBER 27, 2020
Annual Drug Patent Expirations for KORLYM Korlym is a drug marketed by Corcept Therap and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph…. The post New patent for Corcept Therap drug KORLYM appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 30, 2020
Commonly used anti-inflammatory drug added to list of potential treatments
Outsourcing Pharma
NOVEMBER 25, 2020
The new EU Pharmaceutical Strategy, adopted today by the European Commission, is designed to improve and accelerate patientsâ access to safe and affordable medicines and address unmet medical needs in the areas of antimicrobial resistance, cancer, and rare diseases.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Marketing Network
NOVEMBER 19, 2020
The COVID-19 pandemic has undoubtedly accelerated disruption within the digital world. Out of this heavy disruption comes an opportunity for companies to become more innovative-focused and show how quickly they can pivot under pressure. Right now, the pharmaceutical industry is adapting faster than ever before in their marketing strategies due to reduced drug rep access, a (mostly) digital shift, and new and emerging digital and virtual platforms.
NY Times
NOVEMBER 23, 2020
The billionaire is working with the W.H.O., drugmakers and nonprofits to defeat the coronavirus everywhere, including in the world’s poorest nations. Can they do it?
pharmaphorum
NOVEMBER 27, 2020
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.
Drug Patent Watch
NOVEMBER 3, 2020
Annual Drug Patent Expirations for RHOPRESSA Rhopressa is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Aerie Pharms drug RHOPRESSA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 16, 2020
The funds will help expand the scale of SARS-CoV-2 virus sequencing in the hope of revealing new opportunities for intervention
Outsourcing Pharma
NOVEMBER 4, 2020
The agency has chosen Continuity Pharma to aid in development and advancement of continuous manufacturing technology, with the help of a $1.5m grant.
NY Times
NOVEMBER 10, 2020
The German company BioNTech, founded by two scientists, has teamed up with Pfizer on a vaccine that was found to be more than 90 percent effective.
pharmaphorum
NOVEMBER 2, 2020
The pharmaceutical industry has sometimes been a laggard in terms of digital maturity, but the COVID-19 crisis has provided companies the impetus to rapidly implement the most cutting-edge technologies. At the heart of most of these digital advancements is AI and machine learning. With a collective sense of uncertainty, many are pinning their hopes on a vaccine and treatment, and sophisticated technology could help speed up the process of finding an effective medicine.
pharmaphorum
NOVEMBER 23, 2020
Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue. I’m struck by just how much we thrive when we share a common purpose; when – as a society, a group or a family unit – we work together to achieve the same goal. It’s no different in healthcare.
pharmaphorum
NOVEMBER 24, 2020
A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.
pharmaphorum
NOVEMBER 25, 2020
An artificial intelligence tool developed by GE Healthcare twinned with a mobile X-ray device can help the placement of endotracheal tubes (ETTs), a necessary step for COVID-19 patients who require ventilation. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation and make sure ETTs are positioned correctly which should reduce complications.
pharmaphorum
NOVEMBER 11, 2020
Abid Rahman from Intouch Group tells pharmaphorum how AI-based technology is solving challenges across healthcare systems, pharmaceutical companies, and patient treatment. With AI already the key engine for a growing list of consumer devices, the trend has created exciting opportunities for pharma and healthcare. “We have now entered a new phase of AI implementation where AI-based technology is expected to be foundational and not just a novel technology,” Abid Rahman, vice president, innovation,
pharmaphorum
NOVEMBER 25, 2020
AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222. Results announced earlier this week showed that by giving a half dose, followed by a full dose a month later, the vaccine’s efficacy could be boosted from 62% to around 90%.
pharmaphorum
NOVEMBER 25, 2020
Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster Cosentyx for some time.
NY Times
NOVEMBER 19, 2020
In a review of several trials, the World Health Organization found that Gilead’s drug did not improve survival rates for patients nor did it help them recover.
NY Times
NOVEMBER 18, 2020
The company said it planned to apply for emergency approval from the Food and Drug Administration “within days.
pharmaphorum
NOVEMBER 20, 2020
Doctors in the US are to get another option to treat COVID-19 after the FDA granted an Emergency Use Authorization (EUA) for Eli Lilly’s baricitinib. Baricitinib is the active ingredient in Lilly’s rheumatoid arthritis drug Olumiant and is the latest example of a drug being repurposed to combat COVID-19. Most of the drugs attempt to tackle the inflammation that can cause complications in patients with severe disease.
pharmaphorum
NOVEMBER 17, 2020
Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. It can help address well established issues with studies, such as patient recruitment and retention, as well as reducing the need for additional trial protocol amendments.
pharmaphorum
NOVEMBER 11, 2020
In the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been shown to be 92% effective at the interim point of a 40,000-patient study. The preliminary assessment is based on 20 coronavirus cases split between the vaccinated and placebo arms of the study at 21 days, according to a press statement issued this morning by the Gamaleya Institute which developed the shot and the Russian Direct Investment Fund (RDIF).
Pharma Times
NOVEMBER 2, 2020
It is hoped that findings from the NIHR-funded trial will help better inform treatment decisions
pharmaphorum
NOVEMBER 26, 2020
COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how securing supply in a time of crisis will ensure future access, build resilience, and transform relationships.
pharmaphorum
NOVEMBER 24, 2020
The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V ’s efficacy has remained high at 91.4% according to the latest analysis, which comes from almost 19,000 subjects who were assessed seven days after the second dose of the vaccine, administered 28 days after the first.
Pharma Times
NOVEMBER 2, 2020
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
pharmaphorum
NOVEMBER 11, 2020
In the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of Propeller Health about how digital technologies are revolutionising the field of respiratory medicine. The post Health Innovators: David Van Sickle on digital innovation in respiratory medicine appeared first on.
NY Times
NOVEMBER 16, 2020
Moderna is the second company to report preliminary results from a large trial testing a vaccine. But there are still months to go before it will be widely available to the public.
Expert insights. Personalized for you.
145 
Let's personalize your content